Actively Recruiting
Safety and Dose Evaluation of XmAb541 in Advanced Solid Tumors Using Intravenous or Subcutaneous Administration
Led by Xencor, Inc. · Updated on 2026-10-09
282
Participants Needed
27
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational drug XmAb541 to determine its safety, tolerability, and optimal dosing in people with advanced solid tumors such as ovarian cancer, endometrial cancer, and germ cell tumors. This early-phase study aims to assess how XmAb541 affects tumor outcomes and to identify any side effects or toxicities that may occur during treatment. Participants will receive XmAb541 through intravenous or subcutaneous administration during dose escalation and dose expansion phases to find a safe and effective dose. The study carefully monitors participants from the first dose up to two years to track adverse events, dose-limiting toxicities, and cytokine release syndrome. Additional measurements include drug levels in the body and tumor response over time. During the study, participants will undergo regular health assessments including laboratory tests to check liver, kidney, and bone marrow function. Researchers will also evaluate tumor response using circulating tumor DNA and other clinical measures. The study lasts up to two years from the first dose, during which safety and tumor outcomes are closely monitored to guide future research and treatment development.
CONDITIONS
Brief Title
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Research Team
X
XmAb541-01 Central Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here